[ad_1]
Photo EPA / BIONTECH SE / BROCHURE
Britain is the first country to approve the use of Pfizer and BioNTech’s coronavirus vaccine, with delivery beginning next week.
“The government has accepted the recommendation of the Independent Medicines and Health Products Regulatory Authority (MHRA) to approve the use of the Pfizer / BioNTech vaccine,” London said, citing Reuters.
British Health Minister Matt Hancock noted that the country’s vaccination program will start early next week. Hospitals, he said, are already on hold.
“Starting early next week we will start a vaccination program against COVID-19,” the minister told Sky News, referring to “fantastic news.”
As he said, the vaccination program will be initiated by the elderly and the personnel of the care units.
Pfizer spoke of a historic moment in the fight against COVID-19. “This approval is a goal that we have been working towards since we first declared that science will win and we applaud the MHRA for its ability to conduct careful assessment and take timely action to protect the citizens of the UK.” said CEO Albert Burla.
Coreper: When will the vaccine evaluations be completed?
You can tell that Tuesday the European Medicines Agency (EMA) announced that, if the data is sufficient, it will complete the evaluation of the Pfizer and BioNTech vaccine candidate against COVID-19 by December 29.
The EMA also announced that it has applied for a marketing authorization for the candidate vaccine from Moderna Inc and that, if the data is sufficient, it will complete its evaluation of this vaccine before 12 January.
A Commission spokesperson said the European Commission was expected to give final approval for the commercialization of COVID-19 vaccines a few days after the European Medicines Agency gave the green light.
According to a Financial Times publication, the distribution of the vaccine in the European Union not expected to start before January.
Pfizer and BioNTech ask for approval of the vaccine in Europe
It should be noted that the companies Pfizer and BioNTech presented on Tuesday request to the European Medicines Agency for the conditional authorization of your vaccine against coronavirus. A relevant request has been made to the appropriate US authorities.
The two companies announced on November 18 the final results of the third phase of their COVID-19 vaccine, according to which it is 95% effective in preventing infections, without causing serious side effects.
Application for use of Moderna’s vaccine
Monday, the American Moderna Inc. sent the necessary information, for the mRNA vaccine it developed, to the US, European and British watchdogs, requesting the grant of its emergency use.
Their final analysis shows that the vaccine is 94% effective and that it can completely prevent, 100%, severe cases of COVID-19. Furthermore, none of those vaccinated showed serious side effects.
In progress is preparation of primary health care units in Greece.
